Effectiveness seen for RSV lower respiratory tract disease, hospitalized RSV lower respiratory tract disease, PCR-confirmed RSV<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, July 30, 2025 (HealthDay News) — Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according to a study published online July 22 in Pediatrics<\/em>.<\/p>\n Amber Hsiao, Ph.D., M.P.H., from the Kaiser Permanente Vaccine Study Center in Oakland, California, and colleagues examined nirsevimab effectiveness against polymerase chain reaction (PCR)-confirmed RSV LRTD and RSV-associated health care utilization during the 2023 to 2024 RSV season at Kaiser Permanente Northern California.<\/p>\n The study included 31,900 infants, 49.1 percent of whom received nirsevimab. The researchers identified 35 and 462 RSV LRTD episodes among nirsevimab-immunized infants and nonimmunized infants (6.10 and 58.51\/1,000 person-years, respectively). Nirsevimab effectiveness was 87.2, 98.0, and 71.0 percent against RSV LRTD, hospitalized RSV LRTD, and PCR-confirmed RSV, respectively. Fewer encounters (adjusted means difference, \u22120.86) and lower odds of hospitalization (odds ratio, 0.11) were seen for nirsevimab-immunized infants with RSV LRTD than nonimmunized infants.<\/p>\n “These findings support the Advisory Committee on Immunization Practice’s recommendation for eligible infants aged <8 months entering their first RSV season to receive nirsevimab to reduce the risk of RSV infection,” the authors write.<\/p>\n The study was funded by Sanofi, the manufacturer of nirsevimab.<\/p>\n